Fulgent Genetics, Inc. (FLGT): M&A transaction — Fulgent Genetics completes acquisitions of Bako Diagnostics and StrataDx for ~$56.9M cash

Fulgent Genetics, Inc.

Total combined purchase price approximately $56.9 million in cash, subject to post-closing adjustments.
StrataDx acquired for ~$13.5M cash; Bako Diagnostics assets acquired for ~$43.4M cash.
Acquisition includes lease assignment for 29,099 sq ft lab/office in Alpharetta, GA through July 2032.
Advisors: Piper Sandler and Mintz Levin for Fulgent; EV Health Partners and Latham & Watkins for sellers.
Transaction originally announced Dec 22, 2025; closed March 17, 2026.

item 1.01 item 2.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.95

Fulgent Genetics, Inc. completed an acquisition involving Inform Diagnostics, Inc. (closed 2026-03-17).

Action: acquisition
Counterparty: Inform Diagnostics, Inc.
Closing: 2026-03-17

Exact text from the filing

On March 17, 2026, the transactions contemplated by the PSA were completed (the "PSA Closing").

View on SEC.gov

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.95

Fulgent Genetics, Inc. completed an acquisition involving Bako Pathology LP, Bako Pathology Holdings Corp., BPA Holding Corp., Bakotic Pathology Associates, L.L.C., Podceuticals L.L.C., GBRL Consulting (closed 2026-03-17).

Action: acquisition
Counterparty: Bako Pathology LP, Bako Pathology Holdings Corp., BPA Holding Corp., Bakotic Pathology Associates, L.L.C., Podceuticals L.L.C., GBRL Consulting
Closing: 2026-03-17

Exact text from the filing

On March 17, 2026, the transactions contemplated by the APA were completed (the "APA Closing").

View on SEC.gov

Browse all m&a transactions →

Fulgent Genetics, Inc. filing history →

Source: SEC EDGAR

accession 0001674930-26-000012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.